Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin Microneedle Arrays in Basal Cell Cancer
NCT04928222Phase 2Active, not recruiting
- Sponsor
- SkinJect
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of doxorubicin in basal cell carcinoma (BCC) (4 arms), sponsored by SkinJect. Primary endpoints: Eradication of Basal Cell Cancer based on Histologic Analysis at 4 weeks and Number of subjects with dose-limiting toxicity and treatment-related adverse events at 2 weeks. Started Sep 2021; status: active, not recruiting.
02
Drugs
doxorubicin
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04928222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928222.